272BIO Limited

272BIO Ltd is a company focused on developing biotherapeutics for animal health. The company aims to transform veterinary medicine with its cutting-edge solutions. 272BIO Ltd is located in Reading, Berkshire, England, at The Gateway Building, Collegiate Square, Shinfield, RG2 9LH. 272BIO Ltd utilizes innovative technologies to reduce production costs and produce affordable therapies. The company's target industries include Animal Health, Healthcare, and Pharmaceuticals. 272BIO Ltd has a team of experts, including Liz Littlewood as Operations Director, Charles Owen as Founder, Karine Clauwaert in Business Development, An Cerdobbel and Dr Christine Labeur, PhD, as VHH CMC Subject Matter Experts, Emma Campbell as Head of Translational Science, Inês Pimenta de Castro as Head of Portfolio Management, Francois Bertelli as Head of Antibody Discovery, and Tom Hayward as Chief Financial Officer. The company's competitive advantages include 26 years of leadership experience in the Pharma/Biotech Industry, over 20 years’ experience in drug discovery and pre-clinical development, over 24 years of experience in the Pharma industry, and 35 years of scientific career in protein research. 272BIO Ltd's company values and culture are centered around innovation, strategic innovation, data-driven insights, and deep industry experience. The company's email contacts include [email protected], [email protected], and [email protected].